Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
03 11 2021
03 11 2021
Historique:
received:
31
03
2021
accepted:
19
10
2021
revised:
14
09
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
1
2
2022
Statut:
epublish
Résumé
It has been extensively debated whether selective serotonin reuptake inhibitors (SSRIs) are more efficacious than placebo in affective disorders, and it is not fully understood how SSRIs exert their beneficial effects. Along with serotonin transporter blockade, altered dopamine signaling and psychological factors may contribute. In this randomized clinical trial of participants with social anxiety disorder (SAD) we investigated how manipulation of verbally-induced expectancies, vital for placebo response, affect brain monoamine transporters and symptom improvement during SSRI treatment. Twenty-seven participants with SAD (17 men, 10 women), were randomized, to 9 weeks of overt or covert treatment with escitalopram 20 mg. The overt group received correct treatment information whereas the covert group was treated deceptively with escitalopram, described as an active placebo in a cover story. Before and after treatment, patients underwent positron emission tomography (PET) assessments with the [
Identifiants
pubmed: 34732695
doi: 10.1038/s41398-021-01682-3
pii: 10.1038/s41398-021-01682-3
pmc: PMC8566580
doi:
Substances chimiques
Serotonin Plasma Membrane Transport Proteins
0
Serotonin Uptake Inhibitors
0
Citalopram
0DHU5B8D6V
Serotonin
333DO1RDJY
Escitalopram
4O4S742ANY
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
559Informations de copyright
© 2021. The Author(s).
Références
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
J Consult Clin Psychol. 1991 Feb;59(1):12-9
pubmed: 2002127
Neuropsychopharmacology. 2005 May;30(5):996-1005
pubmed: 15770240
Dialogues Clin Neurosci. 2016 Mar;18(1):7-21
pubmed: 27069376
BMC Med Res Methodol. 2011 Jun 10;11:90
pubmed: 21663609
Expert Rev Neurother. 2016;16(4):367-74
pubmed: 26891111
Mol Psychiatry. 2021 Aug;26(8):3970-3979
pubmed: 31822819
J Neurosci. 2003 Dec 10;23(36):11461-8
pubmed: 14673011
Pharmacol Ther. 2000 Jan;85(1):11-28
pubmed: 10674711
Eur Neuropsychopharmacol. 2005 Oct;15(5):521-4
pubmed: 16139170
Neuroimage. 2014 Mar;88:252-62
pubmed: 24121201
J Nucl Med. 2010 Dec;51(12):1885-91
pubmed: 21078806
Biol Psychiatry. 2000 Apr 15;47(8):733-5
pubmed: 10773181
Hum Brain Mapp. 2003 Aug;19(4):224-47
pubmed: 12874777
Metab Brain Dis. 2012 Jun;27(2):151-8
pubmed: 22350963
Arch Gen Psychiatry. 2008 Feb;65(2):220-31
pubmed: 18250260
Mol Psychiatry. 2016 Apr;21(4):523-30
pubmed: 25917369
Prog Brain Res. 2008;172:3-6
pubmed: 18772025
Neuropsychopharmacology. 2003 Feb;28(2):413-20
pubmed: 12589396
Lancet Neurol. 2004 Nov;3(11):679-84
pubmed: 15488461
J Neural Transm (Vienna). 2016 Jul;123(7):679-693
pubmed: 26838982
Psychogeriatrics. 2013 Sep;13(3):189-95
pubmed: 25913769
Eur J Pharmacol. 1991 Jul 23;200(1):1-8
pubmed: 1769366
Neuron. 2005 Apr 7;46(1):65-74
pubmed: 15820694
J Psychopharmacol. 2010 May;24(5):709-16
pubmed: 18838500
J Clin Psychiatry. 2004 Aug;65(8):1064-8
pubmed: 15323590
Sci Transl Med. 2011 Feb 16;3(70):70ra14
pubmed: 21325618
Am J Psychiatry. 2004 May;161(5):826-35
pubmed: 15121647
Eur Neuropsychopharmacol. 2015 Jun;25(6):873-81
pubmed: 25819144
J Cereb Blood Flow Metab. 1996 Sep;16(5):834-40
pubmed: 8784228
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
EBioMedicine. 2017 Oct;24:179-188
pubmed: 29033138
Pharmacol Ther. 2009 Jan;121(1):89-99
pubmed: 19022290
Neuroimage. 2003 Jul;19(3):1233-9
pubmed: 12880848
Eur Neuropsychopharmacol. 2016 Nov;26(11):1775-1783
pubmed: 27642077
JAMA Psychiatry. 2015 Aug;72(8):794-802
pubmed: 26083190
J Neural Transm (Vienna). 2006 May;113(5):659-70
pubmed: 16465456
Arch Gen Psychiatry. 1987 Mar;44(3):259-64
pubmed: 3548638
Lancet Psychiatry. 2014 Oct;1(5):368-76
pubmed: 26361000
Handb Exp Pharmacol. 2014;225:291-303
pubmed: 25304538
Mol Psychiatry. 2018 Aug;23(8):1731-1736
pubmed: 29155804
Front Psychiatry. 2019 Jun 13;10:407
pubmed: 31249537
Biol Psychiatry. 2006 Feb 15;59(4):301-8
pubmed: 16197922
Neuroimage. 1997 Nov;6(4):279-87
pubmed: 9417971
Neurosci Biobehav Rev. 2012 Jan;36(1):79-89
pubmed: 21565217
Biol Psychiatry. 2004 Oct 1;56(7):503-9
pubmed: 15450786
Eur Neuropsychopharmacol. 2007 Feb;17(3):187-93
pubmed: 16757155
Mod Probl Pharmacopsychiatry. 1987;22:141-73
pubmed: 2885745
PLoS One. 2014 Aug 27;9(8):e106337
pubmed: 25162656
Neuropsychopharmacology. 2002 Dec;27(6):949-59
pubmed: 12464452
Neuroimage. 2005 Feb 15;24(4):969-79
pubmed: 15670674
PLoS Med. 2008 Feb;5(2):e45
pubmed: 18303940
Neuroimage. 2006 Oct 1;32(4):1782-92
pubmed: 16757181